Products with Anti-inflammatory bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN6520 | Lupeolic acid |
| 1. Lupeolic acid has anti-inflammatory activity. | |
| BCN6523 | Lysicamine |
| 1. Lysicamine has antimicrobial and anti-inflammation activity, the minimum inhibitory concentrations of the pour component (Streptococcus mutans, Porphyromonas gingivalis, Actinobacillus actinomycetemcomitans and Candida albicans.) is less than 5mg/ml for all four microorganisms and the minimum concentration with anti-inflammation is 0.2mg/ml for both IL-8 and IL-6. 2. Lysicamine has antileishmanial activity. 3. Lysicamine shows significant antioxidant capacity in the ORAC(FL) assay and it is active against S. epidermidis and C. dubliniensis, with MIC values in the range 12.5-100 microg mL(-1). 4. Lysicamine can significantly inhibit the proliferation of melanoma cells, it has antioxidative activity and chemopreventive activity in skin melanoma cells. | |
| BCN6526 | Continentalic acid |
| 1. Continentalic acid and kaurenoic acid are quality control markers in Aralia continentalis. 2. Continentalic acid shows moderate cytotoxicity against A-549 (lung), THP-1 (leukemia) and MCF-7 (breast) cell lines. 3. Continentalic acid exerts significant anti-inflammatory activity. 4. Continentalic acid can efficiently induces apoptosis and is a good candidate for further evaluation as an effective chemotherapeutic agent. 5. Continentalic acid has minimum inhibitory concentrations (MICs) of approximately 8-16 microg/mL against S. aureus, including the MSSA and MRSA standard strains. | |
| BCN6547 | Chelidonic acid |
| 1. Chelidonic acid has therapeutic potential in allergic disorders, it can reduce the levels of the blood eosinophil counts and serum IgE and inhibit histamine release from rat peritoneal mast cells (RPMC) in vitro. 2. Chelidonic acid has shown anti-inflammatory effects, it also can evoke antidepressant-like effect through the up-regulation of BDNF in forced swimming test. | |
| BCN6548 | 4'-Hydroxyflavanone |
| 4'-Hydroxyflavanone may have major potential as a pharmaceutical preparation against hepatic steatosis and dyslipidemia. 4'-Hydroxyflavanone shows full vasorelaxing effects; it also shows inhibition of nitric oxide production in lipopolysaccharide (LPS)-stimulated product of nitrite in RAW 264.7 cells with the IC50 value of 15.72 ug/mL. | |
